Thin Basement Membrane Disease
Thin basement membrane disease is a benign hereditary condition characterized by diffuse thinning of the glomerular basement membrane, typically presenting with persistent microscopic hematuria and a favorable prognosis.
Thin Basement Membrane Disease (TBMD)
Thin Basement Membrane Disease (TBMD) — also historically called Benign Familial Haematuria — is a hereditary glomerular disorder characterised by diffuse thinning of the glomerular basement membrane (GBM) on electron microscopy (EM), presenting clinically with persistent or intermittent microscopic haematuria and a generally benign prognosis [1][2].
Let's break down the name:
- Thin — the defining morphological abnormality: the GBM is roughly half its normal thickness
- Basement membrane — the acellular extracellular matrix layer between podocytes and endothelial cells in the glomerular capillary wall
- Disease — though "benign familial haematuria" was the older term, we now recognise a small minority can progress, so "disease" is more accurate than "nephropathy" (which implies overt kidney damage)
The best imaging modality to visualize thin basement membrane disease is electron microscopy (EM) [1]
Key Concept
TBMD sits on a genetic spectrum with Alport syndrome. Heterozygous COL4A3 or COL4A4 mutations cause TBMD; homozygous or compound heterozygous mutations in the same genes cause autosomal recessive Alport syndrome. Think of TBMD as the "carrier state" of AR Alport syndrome — one hit thins the GBM, two hits destroy it [2][3].
- As common as 5–9% in the general population, but < 1% is clinically diagnosed [2]
- This enormous discrepancy between prevalence and diagnosis reflects that most carriers are completely asymptomatic or have only incidental microscopic haematuria discovered on routine urinalysis (e.g., health checks, pre-employment, pre-school screening) [3]
- TBMD is one of the most common causes of persistent glomerular haematuria in both children and adults [1][3]
- No significant sex predilection (autosomal inheritance), though phenotypic expression can vary
- All ethnicities affected; no particular predilection for Hong Kong Chinese, though the prevalence of isolated microscopic haematuria in Hong Kong school screening programmes is notable (~1–4%), and TBMD accounts for a significant proportion of these cases [3]
Risk Factors
- Family history of haematuria — 30–50% are associated with a family history of haematuria, but the course is generally BENIGN (often clinically silent) [3]
- Heterozygous COL4A3 or COL4A4 mutation carrier status [2]
- Risk factors for progression in the minority who worsen:
- Coexistent proteinuria
- Positive family history of CKD
- Additional "second hits" (e.g., superimposed IgA nephropathy, FSGS, hypertension, diabetes) [2]
3. Anatomy & Function of the Glomerular Basement Membrane
To understand TBMD, you must understand the normal GBM, because the entire disease is about a quantitative defect in this single structure.
The glomerular capillary wall is a three-layered filtration barrier (from blood to urine):
- Fenestrated endothelium — endothelial cells with pores (~70–100 nm) that allow plasma to contact the GBM; these pores are covered by a glycocalyx that repels negatively charged proteins
- Glomerular Basement Membrane (GBM) — the acellular "sieve" composed of extracellular matrix proteins
- Podocytes (visceral epithelial cells) — specialised cells with interdigitating foot processes connected by slit diaphragms (~40 nm gaps) that provide the final size-selective barrier
The GBM is composed of:
- Type IV collagen — the structural backbone; forms a meshwork of triple-helical protomers
- Laminin — cross-links the collagen network
- Nidogen (entactin) — bridges laminin and collagen
- Heparan sulphate proteoglycans (e.g., agrin, perlecan) — provide the negative charge barrier that repels albumin (pI ~4.7, negatively charged at physiological pH)
Type IV collagen has six α-chains (α1–α6), encoded by COL4A1 through COL4A6 genes:
| α-chain pair | Gene pair | Chromosome | Expression |
|---|---|---|---|
| α1/α2 | COL4A1/COL4A2 | Chromosome 13 | Ubiquitous (all basement membranes) |
| α3/α4 | COL4A3/COL4A4 | Chromosome 2 | GBM, cochlea (basilar membrane), lens capsule |
| α5/α6 | COL4A5/COL4A6 | X chromosome | GBM (α5), Bowman's capsule, skin |
During glomerulogenesis, the immature GBM initially contains α1α1α2 networks. As the glomerulus matures, there is a developmental switch to the mature α3α4α5 network. This mature network is:
- More heavily cross-linked (resistant to proteolysis)
- Contains the critical α3, α4, and α5 chains needed for normal GBM thickness and function
Mutations in the type 4 collagen genes cause both Alport syndrome and TBMD [1]
- Normal adult GBM thickness: 300–400 nm [2]
- TBMD GBM thickness: 150–225 nm (roughly half of normal) [2]
- In children, the GBM is physiologically thinner and matures with age, making diagnosis in young children more difficult
Why is the GBM thin in TBMD?
With only one functional copy of COL4A3 or COL4A4, there is haploinsufficiency — roughly half the normal production of α3 or α4 chains. The mature α3α4α5 collagen IV network is quantitatively reduced but not completely absent. The GBM can still assemble but is thinner and more fragile. Contrast this with Alport syndrome (homozygous or X-linked hemizygous), where the network is severely disrupted, leading to irregular thickening, splitting ("basket-weave"), and eventual sclerosis.
4. Aetiology & Pathophysiology
- TBMD is due to heterozygous COL4A3/COL4A4 mutations, i.e., 'carriers' of autosomal recessive (AR) Alport syndrome [2]
- Inheritance: Autosomal Dominant (AD) — because a single heterozygous mutation is sufficient to produce the phenotype [3]
- Over 100 different pathogenic variants have been identified in COL4A3 and COL4A4
- A minority of patients with clinical TBMD have no identifiable COL4A3/4 mutation, suggesting other genetic or non-genetic causes of GBM thinning
Key points along this cascade:
-
Haploinsufficiency: One normal allele produces ~50% of the α-chain. This is enough to assemble a continuous GBM (unlike Alport syndrome where the network is catastrophically disrupted), but the GBM is quantitatively thinner.
-
Localised transient ruptures: The thin GBM is more susceptible to small mechanical tears from normal glomerular filtration pressures. These tears are focal, transient, and self-healing — which is why haematuria can be intermittent [2].
-
Heterozygous defect is sufficient to disrupt GBM architecture to result in haematuria, but not sufficient to provoke the secondary processes that result in proteinuria and progressive CKD as in Alport syndrome [2]. This is the crucial distinction — in Alport syndrome, the severely disrupted GBM triggers podocyte injury, mesangial proliferation, tubulointerstitial fibrosis, and progressive glomerulosclerosis. In TBMD, the GBM is thin but architecturally intact enough that these downstream cascades usually do not occur.
- The GBM's charge barrier (from heparan sulphate proteoglycans) and the podocyte slit diaphragm remain largely intact in TBMD
- The thinning creates holes big enough for RBCs to occasionally squeeze through during transient ruptures, but the overall protein permeability is not significantly increased
- When proteinuria does develop (a minority), it suggests either:
- A second genetic hit
- Superimposed secondary glomerular disease (e.g., FSGS, IgAN)
- Haemodynamic stress (hypertension, hyperfiltration)
| Feature | TBMD | Alport Syndrome |
|---|---|---|
| Genetic defect | Heterozygous COL4A3/4 | Hemizygous COL4A5 (80%, X-linked) or homozygous/compound het COL4A3/4 (AR) |
| GBM on EM | Diffusely thin (150–225 nm) | Irregular thickening + thinning, lamellation, "basket-weave" splitting |
| Light microscopy | Usually normal | Mesangial expansion → FSGS → global sclerosis |
| Immunofluorescence | Negative (no immune deposits) | α5 chain absent from GBM (X-linked) or α3/α4/α5 absent (AR) |
| Clinical course | Generally BENIGN | Progressive to ESKD |
5. Classification
TBMD can be contextualised within broader classification systems:
The modern "COL4A nephropathy" classification (2021 Kashtan revised nomenclature) places TBMD and Alport syndrome on a continuum:
| Category | Genotype | Phenotype |
|---|---|---|
| Alport syndrome (X-linked) | Hemizygous COL4A5 mutation (males) | Progressive haematuria → proteinuria → ESKD + SNHL ± ocular |
| X-linked Alport carrier (female) | Heterozygous COL4A5 | Variable: haematuria ± proteinuria ± CKD (lyonization-dependent) |
| Alport syndrome (AR) | Homozygous/compound het COL4A3 or COL4A4 | Progressive haematuria → proteinuria → ESKD + SNHL ± ocular |
| TBMD (AD carrier state) | Heterozygous COL4A3 or COL4A4 | Isolated haematuria, usually benign |
| Alport syndrome (AD) — rare | Heterozygous COL4A3/4 with dominant-negative effect | Variable CKD progression |
Important Exam Point
Do NOT equate TBMD with "no risk of progression." A minority (~5%) develop progressive CKD, especially those with proteinuria or family history of CKD [2]. The old name "benign familial haematuria" is misleading. Current practice favours genetic testing to clarify the exact mutation and predict risk.
6. Clinical Features
| Symptom | Description | Pathophysiological Basis |
|---|---|---|
| Microscopic haematuria | Persistent or intermittent; usually discovered incidentally on routine urinalysis (health check, pre-employment, pre-school) [2][3] | Transient focal ruptures of the thin, fragile GBM allow RBCs to pass into Bowman's space → appear as dysmorphic RBCs in urine |
| Gross (macroscopic) haematuria | Unusual (< 10%) in TBMD (cf. common in IgAN and Alport) [1][3]; when present, urine may be smoky/cola-coloured | More extensive GBM ruptures, often triggered by intercurrent illness (see below) |
| Gross haematuria preceded by URTI | May occur, mimicking PSGN or IgAN [2] | Systemic inflammatory response → increased glomerular capillary pressure and/or circulating immune complexes → more extensive GBM tears |
| Flank pain | Occasionally accompanies gross haematuria [2] | Distension of the renal capsule from parenchymal oedema or passage of blood clots through the collecting system |
| Asymptomatic | The majority; detected only through screening [3] | GBM thin enough to allow a few RBCs through but no symptoms |
Key Clinical Pearl
The timing of haematuria relative to a pharyngitis episode helps differentiate causes:
- IgA nephropathy: synpharyngitic haematuria — occurs concurrently with URTI (within 1–2 days) [3]
- Post-streptococcal GN (PSGN): haematuria appears 1–3 weeks after pharyngitis (latent period for immune complex formation)
- TBMD: may have episodic gross haematuria with URTI, but the baseline is persistent microscopic haematuria
| Sign | Description | Pathophysiological Basis |
|---|---|---|
| Normal blood pressure | No hypertension (usually) | No significant glomerular scarring → no activation of RAAS, no sodium retention |
| No oedema | No peripheral or periorbital oedema | No significant proteinuria → no hypoalbuminaemia → no oncotic pressure drop |
| No extra-renal manifestations | No hearing loss, no ocular abnormalities | Unlike Alport syndrome, the heterozygous defect does not significantly affect cochlear or lens basement membranes |
| Normal GFR | Renal function tests are normal [3] | GBM is thin but the overall number of functioning nephrons is preserved; no significant glomerulosclerosis |
| Urinalysis findings | Dysmorphic RBCs ± RBC casts; usually < 1 g/day proteinuria (often none) [3] | RBCs become dysmorphic (acanthocytes) as they squeeze through the disrupted GBM; proteinuria is minimal because the charge barrier and slit diaphragms are intact |
Isolated glomerular haematuria presents with normal GFR, no evidence of systemic disease (normal RFT, normal BP), and may be associated with variable proteinuria, but usually < 1 g/day [3]
- Development of proteinuria (particularly > 0.5–1 g/day)
- Rising serum creatinine / declining GFR
- Hypertension
- It is unclear whether TBMD contributed to FSGS in these patients or is just an incidental finding [2]
This is a high-yield exam comparison [1][3]:
| Feature | IgA Nephropathy | Alport Syndrome | TBMD |
|---|---|---|---|
| Onset | Usually adult | Usually childhood | Usually childhood |
| Inheritance | Not Mendelian (may run in families) | X-linked dominant (80%) — no father-to-son transmission [1] | Autosomal dominant |
| Gross haematuria | Common | Common | Unusual (< 10%) [1] |
| Haematuria timing | Synpharyngitic (concurrent with URTI) [3] | Persistent ± episodic gross | Persistent microscopic ± rare gross |
| FHx of CKD | May occur, not specific | Renal failure / deafness primarily in males [1] | FHx of haematuria (not CKD usually) |
| SNHL | No | Yes — high-tone sensorineural hearing loss [1] | No |
| Ocular | No | Yes (anterior lenticonus, dot-and-fleck retinopathy) | No |
| Proteinuria | Variable, may be heavy | Progressive | Usually absent/minimal |
| Prognosis | Variable (30% → ESKD over 20 yr) | Progressive to ESKD | Generally benign |
High-Yield Distinction
For Alport syndrome, one classical symptom apart from renal problems is hearing deficit → diagnosed by pure-tone audiometry (PTA) [1]. If a patient presents with haematuria AND sensorineural hearing loss, Alport syndrome shoots to the top of the differential. TBMD does NOT have extrarenal manifestations.
7. Pathology
- Usually normal or shows only very minor, non-specific changes
- No mesangial proliferation, no crescent formation, no sclerosis (in uncomplicated TBMD)
- Negative — no immune complex deposits (IgA, IgG, IgM, C3 all negative)
- This is critical for distinguishing from IgA nephropathy (which shows mesangial IgA deposits)
- GBM thickness: 150–225 nm (cf. 300–400 nm in normal subjects) [2]
- The thinning is diffuse (involving most capillary loops), not focal
- No "basket-weave" lamellation or splitting (which characterises Alport syndrome)
- Podocyte foot processes are preserved (no effacement, unlike minimal change disease or FSGS)
- No electron-dense deposits
Electron microscopy is the best modality to visualize thin basement membrane disease [1]
8. Approach to a Patient with Isolated Glomerular Haematuria (Clinical Context)
This section outlines the clinical approach you would take when encountering a patient with isolated haematuria and you suspect TBMD. (Full diagnostic workup and management will follow in subsequent sections.)
- Urine microscopy: dysmorphic RBCs, acanthocytes, RBC casts
- Macroscopic haematuria of glomerular origin: painless, smoky brown / cola-coloured, NOT usually associated with clots (clots suggest lower urinary tract source) [3]
- Pure tone audiometry (PTA) for Alport syndrome [1][3]
- Molecular genetic testing for COL4A3-5 mutations in Alport syndrome or TBMD [3]
- Kidney biopsy: usually reserved for those with significant proteinuria (> 1 g/day) or other features [3]
- History + urinalysis of family members — a critical and often overlooked step [1]
When to Biopsy?
Most patients with isolated microscopic haematuria, no proteinuria, normal BP, and normal GFR do NOT need a renal biopsy. Biopsy is indicated when:
- Proteinuria > 1 g/day
- Declining GFR
- Clinical suspicion for a treatable glomerulonephritis
- Potential kidney donors or in genetic counselling [2]
High Yield Summary
Definition: TBMD = hereditary disorder with diffuse GBM thinning (150–225 nm vs normal 300–400 nm) on EM, presenting as isolated glomerular haematuria
Genetics: Heterozygous COL4A3/COL4A4 mutations (AD inheritance) = "carrier state" of AR Alport syndrome
Epidemiology: 5–9% prevalence but < 1% clinically diagnosed
Key Clinical Features:
- Persistent/intermittent microscopic haematuria (gross haematuria unusual, < 10%)
- Normal BP, normal GFR, minimal/no proteinuria
- No extrarenal manifestations (no SNHL, no ocular disease — unlike Alport)
- FHx of haematuria in 30–50%
Pathology: Normal LM, negative IF, thin GBM on EM
Prognosis: Generally benign, but ~5% may progress (especially with proteinuria or FHx of CKD)
Key Distinctions from Alport Syndrome:
- Alport = X-linked (80%), progressive CKD, SNHL, ocular disease, basket-weave GBM on EM
- TBMD = AD, benign course, no extrarenal features, uniformly thin GBM on EM
Diagnosis: EM (gold standard for morphology), genetic testing (COL4A3/4 mutations), clinical context
Active Recall - Thin Basement Membrane Disease
[1] Senior notes: Block A - Glomerular and Tubulo-interstitial Diseases and Acute Kidney Injury.pdf (Alport syndrome and TBMD section) [2] Senior notes: Ryan Ho Urogenital.pdf (Section 3.2.4 Thin Basement Membrane Disease) [3] Senior notes: Ryan Ho Fundamentals.pdf (Section 3.5.4 Isolated Glomerular Haematuria)
Differential Diagnosis of Thin Basement Membrane Disease
When you encounter a patient whose clinical picture suggests TBMD — typically persistent or intermittent microscopic haematuria, normal BP, normal GFR, minimal/no proteinuria — your differential diagnosis operates at two levels:
- Level 1 — Is this actually glomerular haematuria? You must first distinguish glomerular from non-glomerular (urological) causes of haematuria.
- Level 2 — Which glomerular disease? Once glomerular origin is confirmed, you narrow among the classic causes of isolated glomerular haematuria and exclude other glomerulopathies that can present similarly.
The reason this two-tier approach matters is that missing a urological malignancy (e.g., bladder transitional cell carcinoma in an older smoker) while assuming "benign familial haematuria" would be a catastrophic error. Conversely, over-investigating a young patient with isolated microscopic haematuria and a strong family history is wasteful.
Before you even think about TBMD, you must confirm that the haematuria is of glomerular origin [3][4]:
| Feature | Glomerular | Non-Glomerular (Urological) |
|---|---|---|
| Colour | Smoky brown / cola-coloured | Bright red / pink |
| Clots | NOT usually associated with clots | Often has clots |
| RBC morphology | Dysmorphic red cells (acanthocytes) | Isomorphic (normal-shaped) RBCs |
| RBC casts | Present (pathognomonic) | Absent |
| Proteinuria | May be present | Usually absent (unless heavy bleeding) |
| Pain | Usually painless (or flank pain with gross haematuria) | May have dysuria, suprapubic/loin pain |
Glomerular haematuria is evident as > 2 RBC/HPF in spun urine in the form of dysmorphic red cells with irregularities in cell membrane (e.g., acanthocytes) and red cell casts due to conformation to tubular shape [3][4]
Why are the RBCs dysmorphic? As RBCs squeeze through the disrupted GBM and then traverse the renal tubules, they are subjected to osmotic stress (varying tonicity of tubular fluid) and mechanical deformation, producing their characteristic irregular "acanthocyte" morphology. Non-glomerular RBCs bypass the tubules entirely (or enter the urine downstream), so they retain their normal biconcave shape.
These must be systematically excluded before attributing haematuria to TBMD [5][6]:
| Anatomical Site | Differential Diagnoses |
|---|---|
| Kidney (non-glomerular) | Renal cell carcinoma, transitional cell carcinoma (TCC), angiomyolipoma, polycystic kidney disease, renal calculi, pyelonephritis, renal TB, renal artery embolism, renal vein thrombosis, AV malformation, malignant hypertension, hypercalciuria/hyperuricosuria |
| Ureter | Ureteric calculi, ureteric stricture, ureteric malignancy, ureteroiliac fistula |
| Bladder | Cystitis (infective, radiation), TCC, SCC, bladder calculi, recent instrumentation |
| Prostate | BPH, prostate cancer, post-biopsy/TURP |
| Urethra | Urethritis, traumatic catheterisation |
| Systemic | Bleeding diathesis, exercise-induced haematuria, anticoagulant use |
Exclusion of non-glomerular haematuria requires: urine culture, cytology, AFB; cystoscopy + upper tract imaging (KUB, USG, IVP/RP, CTU) [3][4]
Don't Miss This
In any patient > 40 years old with haematuria (even microscopic), urological malignancy (especially bladder TCC) must be excluded before you rest on a diagnosis of TBMD. A cystoscopy and upper tract imaging are essential in this age group, regardless of dysmorphic RBCs. In Hong Kong, nasopharyngeal carcinoma can also present with haematuria from renal metastases (rare but consider in the local context).
4. Level 2 — The "Big Three" of Isolated Glomerular Haematuria
Once you have confirmed glomerular haematuria and excluded non-glomerular causes, the differential diagnoses are classically described to be due to 3 causes [1][3][4]:
- IgA Nephropathy (IgAN)
- Alport Syndrome (Hereditary Nephritis)
- Thin Basement Membrane Disease (TBMD / Benign Familial Haematuria)
These three dominate because they are the main conditions that produce isolated haematuria (i.e., haematuria with normal GFR, normal or near-normal BP, and absent/minimal proteinuria) originating from the glomerulus.
Why it's in the differential: IgAN is the most common glomerulonephritis worldwide and a leading cause of isolated glomerular haematuria. It can present identically to TBMD with persistent microscopic haematuria.
| Feature | Detail |
|---|---|
| Pathogenesis | Galactose-deficient IgA1 (Gd-IgA1) → anti-glycan IgG antibodies form immune complexes → mesangial deposition → complement activation → mesangial proliferation → haematuria ± proteinuria |
| Onset | Usually adult onset (cf. childhood onset in the other two) [3][4] |
| Haematuria pattern | Classically synpharyngitic haematuria (concurrent with URTI) — occurs within 1–2 days of pharyngitis [3][4]. This is because mucosal IgA production surges during infection, increasing circulating Gd-IgA1 and immune complex deposition |
| Gross haematuria | Common [1] |
| Other features | May be associated with history of flank pain and AKI [3][4] |
| Family history | May run in families but no Mendelian inheritance, no one gene [1] |
| Diagnosis | Renal biopsy: mesangial IgA deposits on IF (gold standard); LM shows mesangial proliferation; EM shows mesangial electron-dense deposits |
| Prognosis | Variable — ~30% progress to ESKD over 20 years |
Key Distinguishing Feature
Synpharyngitic haematuria (haematuria concurrent with URTI) is classic for IgAN. This contrasts with PSGN where haematuria appears 2–4 weeks after streptococcal infection (latent period needed for immune complex formation). TBMD haematuria is persistent/intermittent but NOT specifically linked to infection timing [4].
Why it's in the differential: Alport syndrome shares the same genetic locus (COL4A genes) as TBMD and can present early with isolated haematuria before extrarenal features develop.
| Feature | Detail |
|---|---|
| Genetics | Mutations in the type 4 collagen genes [1]; X-linked transmission in 80% (COL4A5 on X chromosome) → father-to-son transmission does not occur [1]. AR form involves COL4A3/4 (same genes as TBMD but homozygous/compound heterozygous) |
| Haematuria | Gross haematuria common [1]; persistent microscopic haematuria from childhood |
| Extrarenal features | Hearing deficit common → pure-tone audiometry (PTA) [1] — Cochlea: ↓ adhesion of the Organ of Corti to the basilar membrane via the defective α3-4-5 type IV collagen → high tone deafness [1]; Ocular: anterior lenticonus, dot-and-fleck retinopathy, recurrent corneal erosion [3] |
| FHx | Renal failure / deafness primarily in males, X-linked dominant mode of inheritance [1] |
| Prognosis | Progressive to ESKD (males with X-linked typically by 20s–30s) |
| Biopsy (EM) | "Basket-weave" GBM — irregular thickening, thinning, and lamellation (cf. uniformly thin GBM in TBMD) |
| Carrier females | Women with X-linked Alport syndrome are heterozygous carriers. Almost all have some degree of haematuria, and some develop renal failure [lyonization] [1] |
How can the three glomerular causes of haematuria be distinguished? → History + urinalysis of family members [1]
Alport vs TBMD — The Core Distinction
Think of it on a spectrum:
- TBMD = one hit (heterozygous COL4A3/4) → thin but intact GBM → haematuria only → benign
- Alport (AR) = two hits (homozygous COL4A3/4) → disrupted GBM → progressive CKD + SNHL + ocular
- Alport (X-linked) = hemizygous COL4A5 in males → disrupted GBM → progressive CKD + SNHL + ocular
The clinical "tell" is the extrarenal features (hearing loss, eye disease) and the family history pattern (X-linked with no male-to-male transmission vs. AD in TBMD).
The features that favour TBMD over the other two:
- Gross haematuria unusual (< 10%) [1][3]
- AD inheritance; 30–50% with FHx of haematuria, but course generally BENIGN (often clinically silent) [3][4]
- No extrarenal features (no SNHL, no ocular disease)
- No progressive CKD (in the vast majority)
- D/dx: IgA nephropathy, Alport syndrome (FHx of renal failure, X-linked inheritance) [2]
Beyond the "big three," other glomerulopathies can occasionally mimic TBMD's presentation of isolated haematuria. These are less common in this clinical context but must be considered, particularly when atypical features are present:
| Condition | Why Consider | How to Distinguish |
|---|---|---|
| Post-streptococcal GN (PSGN) | Haematuria after URTI | Latent period 2–4 weeks post-infection; low C3; nephritic syndrome with hypertension, oedema, oliguria |
| Lupus nephritis (early) | Young females with haematuria | ANA+, anti-dsDNA+, low C3/C4; systemic SLE features (malar rash, arthritis, serositis) |
| ANCA-associated vasculitis (early) | Haematuria with systemic symptoms | ANCA+, constitutional symptoms, skin/lung/ENT involvement; rapidly progressive |
| Anti-GBM disease (early) | Haematuria with pulmonary symptoms | Anti-GBM antibodies+; pulmonary haemorrhage; Goodpasture syndrome is a medical emergency [7] |
| Mesangioproliferative GN (non-IgA) | Isolated haematuria | Diagnosis by biopsy: mesangial deposits that are NOT IgA (e.g., IgM, C3) |
| Hereditary nephritis (non-Alport) | FHx of haematuria/CKD without COL4A mutations | Rare; other basement membrane gene mutations (e.g., LAMB2, MYH9-related) |
| Nutcracker syndrome | Left renal vein compression between aorta and SMA → haematuria | Usually orthostatic; Doppler US shows left renal vein compression; NOT glomerular (isomorphic RBCs) |
| Loin pain-haematuria syndrome | Recurrent flank pain + haematuria | Diagnosis of exclusion; no specific pathology; often in young women |
Exclusion of other glomerulopathies requires: urine sediment, urine protein quantification, RFT, and selected serologies (e.g., C3/4, ANA) [3][4]
An important but often overlooked concept: TBMD is common (5–9% prevalence), so it can coexist with other renal pathologies. When a patient with known TBMD develops new features (proteinuria, declining GFR, nephrotic syndrome), consider superimposed:
- IgA nephropathy — the most common coexisting glomerulopathy; both are common enough to overlap
- Focal segmental glomerulosclerosis (FSGS) — it is unclear whether TBMD contributed to FSGS in these patients or is just an incidental finding [2]
- Diabetic nephropathy — in the setting of diabetes
- Hypertensive nephrosclerosis — in the setting of longstanding hypertension
This is one of the highest-yield exam tables for nephrology [1][2][3][4]:
| Feature | IgA Nephropathy | Alport Syndrome | TBMD |
|---|---|---|---|
| Inheritance | Not Mendelian; may run in families, no one gene [1] | X-linked dominant (80%); father-to-son does NOT occur [1]; AR (15%); AD rare | AD (heterozygous COL4A3/4) [2] |
| Gene | Polygenic / environmental | COL4A5 (X-linked); COL4A3/4 (AR) | COL4A3 or COL4A4 |
| Age of onset | Usually adult [3] | Usually childhood | Usually childhood |
| Gross haematuria | Common [1] | Common [1] | Unusual (< 10%) [1] |
| Haematuria pattern | Synpharyngitic [3] | Persistent ± episodic gross | Persistent/intermittent microscopic |
| Extrarenal features | Nil (may have HSP overlap with skin/joint/GI) | SNHL (high-tone) + ocular (anterior lenticonus, dot-and-fleck retinopathy) [1][3] | None |
| FHx | Variable; non-Mendelian | CKD/deafness in males [1] | Haematuria in relatives (30–50%); benign [3] |
| Proteinuria | Variable (can be heavy) | Progressive | Minimal/absent |
| Prognosis | 30% → ESKD over 20 yr | Progressive → ESKD | Generally benign; ~5% progressive [2] |
| Biopsy — LM | Mesangial proliferation | Mesangial expansion → FSGS → sclerosis | Normal |
| Biopsy — IF | Mesangial IgA deposits (diagnostic) | α5 chain absent from GBM (X-linked) | Negative |
| Biopsy — EM | Mesangial electron-dense deposits | Basket-weave lamellation of GBM | GBM 150–225 nm (thin), no lamellation [2] |
| Definitive test | Renal biopsy | PTA + COL4A3-5 genetic testing [3] | EM (if biopsied) + COL4A3/4 genetic testing [2][3] |
Common Exam Mistakes
-
Assuming all haematuria is glomerular — always check for dysmorphic RBCs/casts before attributing to TBMD. Missing a bladder TCC is a life-threatening error.
-
Confusing TBMD with early Alport syndrome — in a child with isolated haematuria, both can look identical. The distinguishing features (SNHL, ocular disease, progressive CKD) may not yet be apparent. History + urinalysis of family members is critical [1]. Genetic testing for COL4A3-5 resolves this definitively.
-
Calling TBMD "benign" without qualification — a minority (~5%) develop progressive CKD [2]. Patients with proteinuria or FHx of CKD need monitoring, not reassurance alone.
-
Forgetting female Alport carriers — Women with X-linked Alport are heterozygous carriers; almost all have some degree of haematuria, and some develop renal failure due to lyonization [1]. They can be misdiagnosed as TBMD.
-
Not considering coexisting pathology — TBMD is so common (5–9%) that it frequently coexists with other glomerular diseases. If the clinical picture changes (new proteinuria, declining GFR), re-evaluate rather than blaming TBMD.
High Yield Summary
Two-level differential approach:
- Level 1: Glomerular (dysmorphic RBCs, casts) vs. non-glomerular (urological workup mandatory)
- Level 2: Among the "Big Three" of isolated glomerular haematuria — IgAN, Alport syndrome, TBMD
Key differentiators for TBMD:
- Gross haematuria unusual (< 10%) — cf. common in IgAN and Alport
- AD inheritance, FHx of haematuria (not CKD)
- No extrarenal features (no SNHL, no ocular disease)
- Normal GFR, minimal proteinuria
Most important tool: History + urinalysis of family members
Must exclude: Non-glomerular causes (especially urological malignancy in > 40 y/o); other glomerulopathies with serologies (C3/C4, ANA, ANCA, anti-GBM)
Beware: Female X-linked Alport carriers can mimic TBMD; resolve with genetic testing
Active Recall - Differential Diagnosis of TBMD
References
[1] Senior notes: Block A - Glomerular and Tubulo-interstitial Diseases and Acute Kidney Injury.pdf (Alport syndrome and TBMD section) [2] Senior notes: Ryan Ho Urogenital.pdf (Section 3.2.4 Thin Basement Membrane Disease) [3] Senior notes: Ryan Ho Fundamentals.pdf (Section 3.5.4 Isolated Glomerular Haematuria) [4] Senior notes: Adrian Lui Pediatrics Notes.pdf (Section 9.2.2 Hematuria and Acute Nephritic Syndrome) [5] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Causes of haematuria differential table) [6] Senior notes: MBBS Final MB (Surgery) (Felix PY Lai).pdf (Causes of haematuria differential table) [7] Senior notes: Block A – Nephrology Data Interpretation.pdf (Goodpasture syndrome discussion)
Diagnostic Criteria, Algorithm & Investigations for TBMD
Unlike many glomerular diseases, TBMD does not have a formal set of diagnostic criteria published by a consensus body (e.g., no "ACR criteria" or "KDIGO criteria" for TBMD). Instead, the diagnosis is made through a clinical-pathological-genetic approach — essentially a synthesis of compatible clinical features, exclusion of mimics, and confirmatory findings on biopsy or genetic testing.
Diagnosis of TBMD is usually clinical [2]. The working diagnostic framework can be summarised as:
| Criterion | Requirement |
|---|---|
| 1. Glomerular haematuria | Persistent or intermittent microscopic haematuria with dysmorphic RBCs ± RBC casts |
| 2. Preserved renal function | Normal GFR, normal or near-normal BP, minimal proteinuria (usually < 1 g/day) |
| 3. No systemic features | No SNHL, no ocular disease, no constitutional symptoms |
| 4. Compatible family history | AD pattern of haematuria in relatives (30–50%) WITHOUT progressive CKD or deafness |
| 5. Exclusion of mimics | Non-glomerular causes excluded; other glomerulopathies excluded by serologies |
| 6. Confirmatory test (when performed) | EM: GBM 150–225 nm (cf. 300–400 nm in normal subjects) [2], negative IF, normal LM; AND/OR Genetics: Heterozygous COL4A3/COL4A4 pathogenic variant |
When Is the Diagnosis 'Clinical' vs 'Definitive'?
Clinical diagnosis: A young patient with isolated microscopic haematuria, normal RFT, normal BP, no proteinuria, AD FHx of haematuria without CKD, and negative serological workup → highly likely TBMD. No biopsy or genetic testing needed in most cases.
Definitive diagnosis: Requires either:
- Renal biopsy showing GBM 150–225 nm on EM [2], or
- Molecular genetic testing confirming heterozygous COL4A3 or COL4A4 mutation [3][4]
Most patients are managed on a clinical diagnosis alone. Biopsy and genetic testing are reserved for specific indications (see below).
Kidney biopsy is usually reserved for those with significant proteinuria ( > 1 g/day) or other features of progressive renal diseases [3][4]
Additional indications [2][6]:
- Renal biopsy may also be indicated in potential kidney donors or in genetic counselling [2]
- Rising serum creatinine / declining GFR — to look for superimposed or alternative pathology
- Diagnostic uncertainty (e.g., cannot distinguish TBMD from early Alport syndrome clinically)
- Atypical features (e.g., nephrotic-range proteinuria, hypertension, systemic symptoms)
Why is biopsy not routinely done? Because:
- It is invasive (risk of bleeding, infection, AV fistula, loss of nephrons)
- The clinical diagnosis is usually sufficient when the presentation is classic
- The therapeutic implications are minimal — most patients with TBMD need only monitoring
- Renal biopsy is indicated in patients with glomerular haematuria or with risk factors for progressive diseases such as proteinuria or elevation in serum creatinine concentration [6]
Contraindications to percutaneous renal biopsy [6]:
- Bleeding diathesis
- Severe hypertension (uncontrolled)
- Solitary kidney
- Small/contracted kidneys (chronic irreversible disease — you'd get fibrous tissue)
- Hydronephrosis
- Large cysts (cannot stop bleeding)
- Renal or perirenal infection
The algorithm below integrates the two-level approach (glomerular vs non-glomerular → specific glomerular diagnosis) with the specific investigations needed at each step:
4. Investigation Modalities — Systematic Breakdown
This is the first and most important investigation. It answers the fundamental question: is this glomerular or non-glomerular haematuria?
| Test | Expected Finding in TBMD | Interpretation / Why |
|---|---|---|
| Urine dipstick | Positive for blood; trace or negative for protein | Haem group on RBCs reacts with dipstick; minimal proteinuria because GBM charge barrier and slit diaphragms intact |
| Urine microscopy | > 2 RBC/HPF in spun urine; dysmorphic RBCs (acanthocytes); ± RBC casts [3][4] | Dysmorphic morphology from osmotic/mechanical stress as RBCs traverse thin GBM and renal tubules. RBC casts form when RBCs are entrapped in Tamm-Horsfall protein matrix within tubules — casts have an organic matrix composed primarily of Tamm-Horsfall mucoprotein [8] |
| Urine culture | Negative | Excludes UTI as cause of haematuria |
| Urine cytology | Negative for malignant cells | Excludes TCC / urothelial malignancy |
| Urine AFB | Negative | Excludes renal tuberculosis |
Exclusion of non-glomerular haematuria: urine culture, cytology, AFB [3][4]
Why dysmorphic RBCs are pathognomonic of glomerular origin: When RBCs pass through the disrupted GBM, they undergo mechanical deformation (squeezed through tiny gaps in the thinned membrane). They then travel through the tubular system where the osmolality varies dramatically (from ~50 mOsm/kg in the dilute descending limb to ~1200 mOsm/kg in the medullary collecting duct). This osmotic stress causes membrane blebbing and creates the characteristic "acanthocyte" morphology — spiculated RBCs with vesicle-shaped protrusions. A threshold of > 5% acanthocytes in the urine sediment is highly specific for glomerular origin.
| Test | Expected in TBMD | Why This Matters |
|---|---|---|
| 24-hour urine protein | Usually < 0.15 g/day (normal) or < 1 g/day [4] | Gold standard for quantification but cumbersome [9] — patient must collect all urine for 24 hours |
| Spot urine protein-to-creatinine ratio (uPCR) | Normal or mildly elevated | Alternative to 24h collection; done on first morning void; much more convenient [9]. In QMH, uPCR is preferred [9] |
| Urine albumin-to-creatinine ratio (UACR) | Normal or mildly elevated | Especially for diabetic patients or CKD patients; more sensitive for detecting early albuminuria [9]. ACR and urine albumin level are more sensitive for screening proteinuria [8] |
Proteinuria Quantification in TBMD
The degree of proteinuria is the most important prognostic marker in TBMD. Patients with persistent proteinuria > 0.5–1 g/day are at higher risk of progression and warrant closer monitoring, ACEI/ARB therapy, and consideration of renal biopsy [2]. The absence of significant proteinuria is what makes TBMD "benign" in most cases.
| Test | Expected in TBMD | Interpretation |
|---|---|---|
| Serum creatinine | Normal (65–90 μmol/L in adults, age-dependent) [10] | Normal because the overall number of functioning nephrons is preserved. When creatinine rises, GFR has already been reduced by at least 50% [10] — so a normal creatinine in TBMD is reassuring |
| Serum urea/BUN | Normal | Urea can be elevated in pre-renal states or high protein intake; normal in TBMD |
| eGFR | Normal ( > 90 mL/min/1.73m²) | Calculated by CKD-EPI formula; confirms preserved renal function |
| Electrolytes (Na, K, Cl) | Normal | No tubular dysfunction in TBMD |
Basic laboratory investigations: blood for renal function test — urea and creatinine concentration [7]
This is a critical step in the diagnostic algorithm. The purpose is to exclude immune-mediated glomerulonephritides that could present with haematuria:
| Test | Expected in TBMD | What It Excludes | Rationale |
|---|---|---|---|
| C3/C4 | Normal | Lupus nephritis, PSGN, MPGN, cryoglobulinaemia | ↓C3/4 generally indicates immune complex-mediated GN [3][11] |
| ANA | Negative | SLE / lupus nephritis | Anti-nuclear antibodies target nuclear components; positive in > 95% of SLE |
| Anti-dsDNA | Negative | SLE / lupus nephritis | More specific than ANA for SLE |
| ANCA | Negative | ANCA-associated vasculitis (GPA, MPA) | Antibodies against neutrophil cytoplasmic antigens; positive in pauci-immune vasculitis [12] |
| Anti-GBM antibody | Negative | Goodpasture syndrome [7][12] | Antibodies against α3 chain of type IV collagen in GBM; Goodpasture syndrome is a medical emergency [7] |
| ASLO titre | Normal | PSGN | Confirms recent streptococcal infection; relevant if haematuria follows pharyngitis by 2–4 weeks |
| Serum IgA | Normal | IgA nephropathy | Elevated in ~50% of IgAN but not specific |
| HBsAg, anti-HCV | Context-dependent | HBV/HCV-related MPGN | Important in Hong Kong given HBV prevalence |
Exclusion of other glomerulopathies: urine sediment, urine protein quantification, RFT; selected serologies, e.g. C3/4, ANA [3][4]
Further investigations required include: immune marker panel — C3 and C4 for lupus nephritis; ANA and anti-dsDNA for lupus nephritis; ANCA for pauci-immune vasculitis; anti-GBM antibody for Goodpasture's syndrome [12]
Complement Levels — A Quick Differentiation Tool
↓C3/C4 → Think immune complex-mediated GN: lupus nephritis, PSGN, MPGN, cryoglobulinaemia, IE/shunt nephritis
Normal C3/C4 → Think non-immune-complex GN (except IgAN which is IC-mediated but usually has normal complement): PAN, Goodpasture, HSP/IgAN, ANCA vasculitis, TBMD [11]
TBMD has normal complement because there is NO immune complex deposition — the pathology is purely structural (thin GBM from collagen deficiency).
| Test | Expected in TBMD | What It Detects |
|---|---|---|
| Pure tone audiometry | Normal | Hearing deficit is a classical symptom of Alport syndrome → PTA detects high-tone sensorineural hearing loss [1][3][4] |
Why this is done: PTA is a non-invasive, inexpensive screening test that can rapidly distinguish Alport syndrome from TBMD. In Alport syndrome, the defective α3-4-5 type IV collagen in the cochlear basilar membrane leads to ↓ adhesion of the Organ of Corti to the basilar membrane → high tone deafness [1]. This is ABSENT in TBMD because the heterozygous defect does not significantly affect cochlear function.
| Test | Expected in TBMD | What It Detects |
|---|---|---|
| Slit-lamp examination | Normal | Anterior lenticonus (pathognomonic for Alport syndrome) |
| Fundoscopy | Normal | Dot-and-fleck retinopathy (Alport syndrome) |
These extrarenal features are absent in TBMD. Their presence immediately shifts the diagnosis to Alport syndrome.
| Test | Expected in TBMD | Purpose |
|---|---|---|
| USG kidneys | Normal-sized kidneys, normal cortical echogenicity, no obstruction, no masses | Excludes structural causes (PKD, hydronephrosis, masses). Parenchymal changes → whitening of kidney on US, indicates chronic change, loss of corticomedullary differentiation — this would be ABSENT in TBMD [9]. Small kidneys → CKD [9] |
| CT urography | Normal | Preferred initial imaging for unexplained haematuria; higher sensitivity for renal mass, calculi, TCC [6] — mainly for excluding urological causes |
| Cystoscopy | Normal | Only modality that permits visualization of urethra, prostate and entire bladder for malignancy and identify source of bleeding [6] — essential in patients > 40 years |
| DTPA scan | Normal perfusion and drainage | DTPA for renal perfusion and drainage [9] — rarely needed in TBMD |
| DMSA scan | No scarring | DMSA for renal scarring [9] — rarely needed in TBMD |
Exclusion of non-glomerular haematuria: cystoscopy + upper tract imaging (KUB, USG, IVP/RP, CTU) [3][4]
Renal biopsy is the definitive morphological investigation but is not routinely performed in TBMD. When done, it requires three components of analysis:
| Component | TBMD Finding | Why / Interpretation |
|---|---|---|
| Light Microscopy (LM) | Normal — no mesangial proliferation, no crescents, no sclerosis | The heterozygous collagen defect does not provoke inflammation or scarring detectable by LM. Contrast with IgAN (mesangial proliferation) or Alport (mesangial expansion → FSGS) |
| Immunofluorescence (IF) | Negative — no IgA, IgG, IgM, C3, C4, C1q deposits | There is NO immune complex deposition in TBMD — the pathology is structural, not immunological. This distinguishes TBMD from IgAN (mesangial IgA) and lupus nephritis (full-house pattern). Immunofluorescence pattern is most helpful for diagnosis [11] |
| Electron Microscopy (EM) | GBM 150–225 nm (cf. 300–400 nm in normal subjects) [2]; diffuse uniform thinning; no basket-weave; no electron-dense deposits; foot processes preserved | Best imaging modality to visualize thin basement membrane disease is electron microscopy [1]. The thinning is uniform (unlike Alport where it alternates thick/thin with lamellation). Foot processes are NOT effaced (unlike MCD/FSGS) |
Most common biopsy finding [in glomerular haematuria workup] is IgA nephropathy, hereditary nephritis, non-specific glomerulonephritis and basement membrane diseases (e.g. benign familial haematuria) [6]
Practical biopsy procedure [9]:
- Patient prone, radiologist uses ultrasound guidance
- Lower pole of kidney targeted
- Multiple cores taken to ensure sufficient tissue for all three analyses (LM, IF, EM)
- At least 8–10 glomeruli needed for adequate assessment
Biopsy Interpretation: TBMD vs Alport vs IgAN
| Finding | TBMD | Alport Syndrome | IgA Nephropathy |
|---|---|---|---|
| LM | Normal | Mesangial expansion → FSGS | Mesangial proliferation |
| IF | Negative | α5 chain absent from GBM (X-linked); or α3/4/5 absent (AR) | Mesangial IgA deposits (diagnostic) |
| EM | Uniform thin GBM (150–225 nm) | Irregular thickening + thinning, basket-weave lamellation | Mesangial electron-dense deposits |
| Test | Finding in TBMD | Interpretation |
|---|---|---|
| Molecular genetic testing for COL4A3-5 mutations | Heterozygous pathogenic variant in COL4A3 or COL4A4 [3][4] | Confirms the diagnosis definitively; distinguishes from Alport syndrome (hemizygous COL4A5 or homozygous COL4A3/4) and female X-linked Alport carriers (heterozygous COL4A5) |
Why genetic testing is increasingly preferred over biopsy:
- Non-invasive (blood or saliva sample)
- Can be done at any age (including children where GBM thickness norms are less established)
- Identifies the exact mutation — allows genotype-phenotype correlation and prognostic counselling
- Enables family screening — identify at-risk relatives before clinical manifestations
- Essential for genetic counselling — clarify risk of offspring inheriting two mutations (AR Alport) if both parents are carriers
Current approach (2024–2026): Genetic testing with next-generation sequencing (NGS) panels covering COL4A3, COL4A4, and COL4A5 is becoming first-line in many centres, potentially replacing biopsy for diagnosis of COL4A nephropathies. The Alport Syndrome Classification Working Group recommends genetic testing as the primary diagnostic tool [KDIGO 2024 consensus].
History + urinalysis of family members is a critical and often underutilised investigation [1]:
| Test on Relatives | Purpose | Expected in TBMD Families |
|---|---|---|
| Urinalysis | Detect haematuria in relatives | Multiple family members with isolated microscopic haematuria across generations (AD pattern) |
| RFT | Detect CKD in relatives | Normal — if progressive CKD found, reconsider Alport syndrome |
| PTA | Screen for SNHL | Normal — if SNHL found, reconsider Alport syndrome |
| Genetic testing | Confirm carrier status | Heterozygous COL4A3/4 mutation in affected relatives |
Thin basement membrane disease runs in families as well [1]; 30–50% associated with FHx of haematuria, but generally BENIGN in course (often clinically silent) [3]
| Clinical Scenario | Most Likely Diagnosis | Key Investigation Finding |
|---|---|---|
| Microscopic haematuria + normal RFT + normal BP + AD FHx of haematuria only + no SNHL | TBMD | Clinical diagnosis; EM if biopsied: thin GBM; genetics: het COL4A3/4 |
| Microscopic haematuria + synpharyngitic gross haematuria + adult onset | IgA Nephropathy | Renal biopsy: mesangial IgA on IF |
| Microscopic haematuria + progressive CKD + SNHL + X-linked FHx | Alport Syndrome | PTA: high-tone SNHL; genetics: COL4A5 mutation; biopsy: basket-weave on EM |
| Microscopic haematuria + low C3/C4 + ANA+ + anti-dsDNA+ | Lupus Nephritis | Biopsy: various classes; IF: full-house pattern |
| Microscopic haematuria + anti-GBM+ + haemoptysis | Goodpasture Syndrome | Biopsy: linear IgG staining on GBM; cellular crescents [12] |
| Microscopic haematuria + ANCA+ + constitutional symptoms | ANCA Vasculitis | Biopsy: pauci-immune crescentic GN |
High Yield Summary
Diagnosis of TBMD is usually clinical — based on isolated glomerular haematuria + normal RFT/BP + AD FHx of benign haematuria + absence of extrarenal features + negative serologies.
Key investigations:
- Urinalysis: Dysmorphic RBCs ± RBC casts confirm glomerular origin
- Urine protein quantification: < 1 g/day (uPCR or UACR preferred over 24h collection)
- RFT: Normal creatinine and eGFR
- Serologies: C3/C4, ANA, ANCA, anti-GBM — all normal; purpose is to exclude immune-mediated GN
- PTA: Normal (excludes Alport syndrome SNHL)
- Imaging: USG kidneys normal; cystoscopy/CTU for patients > 40 years to exclude urological malignancy
- Renal biopsy: Reserved for proteinuria > 1 g/day, declining GFR, diagnostic uncertainty, or donor evaluation → EM shows GBM 150–225 nm, LM normal, IF negative
- Genetic testing: Heterozygous COL4A3/4 mutation — increasingly first-line; definitive
- Family screening: Urinalysis + RFT + PTA of relatives
Biopsy indications: Proteinuria > 1 g/day, rising Cr, potential kidney donors, genetic counselling
Active Recall - Diagnosis & Investigations of TBMD
References
[1] Senior notes: Block A - Glomerular and Tubulo-interstitial Diseases and Acute Kidney Injury.pdf (Alport syndrome and TBMD section) [2] Senior notes: Ryan Ho Urogenital.pdf (Section 3.2.4 Thin Basement Membrane Disease) [3] Senior notes: Ryan Ho Fundamentals.pdf (Section 3.5.4 Isolated Glomerular Haematuria) [4] Senior notes: Adrian Lui Pediatrics Notes.pdf (Section 9.2.2 Hematuria and Acute Nephritic Syndrome) [6] Senior notes: MBBS Final MB (Surgery) (Felix PY Lai).pdf (Haematuria investigations and renal biopsy) [7] Senior notes: Block A - Nephrotology Teaching Clinic RTD.pdf (Renal pathology and biopsy) [8] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Urinalysis and laboratory interpretation) [9] Senior notes: Block A - Introduction to Renal Investigations (RFT, urine tests and US kidneys).pdf [10] Senior notes: Block A - Nephrology Interactive Tutorial.pdf (Creatinine and AKI discussion) [11] Senior notes: Ryan Ho Urogenital.pdf (Section 3.2 — complement levels in GN evaluation) [12] Senior notes: Block A – Nephrology Data Interpretation.pdf (Goodpasture syndrome and serological workup)
Management of Thin Basement Membrane Disease
The management of TBMD is fundamentally different from most other glomerular diseases. There is no disease-modifying therapy that can "fix" the underlying heterozygous COL4A3/4 mutation or thicken the GBM. Instead, management is built on three pillars:
- Reassurance and education — the vast majority have a benign course
- Risk stratification — identify the minority (~5%) who may progress
- Targeted intervention — treat only when there are features suggesting progression (proteinuria, hypertension, declining GFR)
This is a condition where doing less is often the correct answer — but you must know when to escalate.
3. Management by Risk Category
3.1 Low-Risk Patients — The Majority
Profile: Isolated microscopic haematuria, no proteinuria, normal BP, normal GFR, no family history of CKD.
This is the typical TBMD patient. The key interventions are:
- Explain that TBMD is a genetic structural variant, not a "dangerous kidney disease"
- The old name "benign familial haematuria" captures the prognosis for most patients
- Haematuria will likely persist lifelong but is not harmful in itself
- Prognosis is usually benign [2]
- Advise the patient that no dietary restrictions are needed
- Explain that no specific treatment exists for the underlying defect
Annual monitoring for microalbuminuria/proteinuria [2] — this is the cornerstone of long-term follow-up:
| Parameter | Frequency | Purpose | Why |
|---|---|---|---|
| Urinalysis | Annual | Confirm persistent haematuria; detect new proteinuria | Development of proteinuria is the key sentinel event signalling potential progression |
| uPCR or UACR | Annual | Quantify any proteinuria | A rising uPCR from normal to > 0.5 g/day should trigger re-evaluation |
| RFT (creatinine, eGFR) | Annual | Monitor renal function | A rising creatinine means GFR has already fallen by ≥ 50% (creatinine is an insensitive marker in early CKD) |
| Blood pressure | Annual | Detect hypertension | Hypertension both signals and accelerates glomerular injury |
Why Annual Monitoring Matters
Even though the prognosis is benign for most, a minority (5%) develop progressive CKD, especially those who have proteinuria or positive FHx of CKD [2]. The purpose of annual monitoring is to catch the transition from "benign haematuria" to "progressive disease" early — while intervention (ACEI/ARB) can still make a difference.
| Recommendation | Rationale |
|---|---|
| No activity restriction | Unlike some cardiac conditions, there is no evidence that exercise worsens TBMD. Exercise-induced gross haematuria may occasionally occur but is self-limiting |
| Adequate hydration | General kidney health; reduces risk of stone formation if hypercalciuria coexists |
| Avoid nephrotoxins | NSAIDs, aminoglycosides, and iodinated contrast should be used cautiously — while the kidneys are normal, preserving nephron mass is prudent in anyone with a baseline structural abnormality |
| Report new symptoms | Instruct patients to seek medical attention if they develop foamy urine (proteinuria), ankle swelling (oedema), or persistent hypertension |
3.2 Moderate-Risk Patients
Profile: Trace to mild proteinuria (0.5–1 g/day) OR positive family history of CKD (suggesting possible more severe genetic variant or coinheritance).
- 6-monthly rather than annual check: urinalysis, uPCR/UACR, RFT, BP
- Consider genetic testing (COL4A3/4 panel) if not yet done — to clarify the exact mutation and inform prognosis
ACEI/ARB only for patients who also have proteinuria > 0.5–1 g/day or ↑BP or ↑Cr/↓GFR [2]
Why ACEI/ARB? The rationale is the same as in any proteinuric glomerular disease — it is about reducing intraglomerular pressure and proteinuria:
-
Efferent arteriolar dilation: ACEI (angiotensin-converting enzyme inhibitor; "ACE" = the enzyme that converts angiotensin I → II; "inhibitor" = blocks it) and ARB (angiotensin II receptor blocker) both reduce the action of angiotensin II. Angiotensin II preferentially constricts the efferent arteriole of the glomerulus. By blocking this:
- Efferent arteriole relaxes → intraglomerular pressure drops → less hydrostatic force driving protein across the GBM
- This reduces proteinuria (the "anti-proteinuric" effect)
-
Reduction of TGF-β and fibrotic mediators: Angiotensin II stimulates TGF-β production in mesangial cells → promotes extracellular matrix deposition → glomerulosclerosis. Blocking this pathway slows fibrosis.
-
Net effect: Slows progression of proteinuria and CKD in any glomerular disease with proteinuria, including TBMD with emerging proteinuria.
| Drug Class | Examples | Dose | Key Points |
|---|---|---|---|
| ACEI | Ramipril, Perindopril, Lisinopril | Titrate to maximum tolerated dose | First-line; monitor K+ and creatinine 1–2 weeks after initiation (expect up to 30% rise in Cr — acceptable; if > 30% rise, suspect renal artery stenosis) |
| ARB | Losartan, Valsartan, Irbesartan | Titrate to maximum tolerated dose | Alternative if ACEI-intolerant (cough — due to bradykinin accumulation in ACEI, not ARB) |
Contraindications to ACEI/ARB:
- Bilateral renal artery stenosis (blocks the compensatory efferent constriction that maintains GFR in stenotic kidneys → precipitous GFR drop)
- Pregnancy (teratogenic — causes renal agenesis, oligohydramnios, Potter sequence)
- Severe hyperkalaemia (K+ > 5.5 mmol/L) — ACEI/ARB reduce aldosterone → reduce K+ excretion
- Known allergy/angioedema to ACEI (for ACEI-specific; can trial ARB with caution)
Target: Reduce proteinuria to < 0.5 g/day if possible; maintain BP < 130/80 mmHg (or < 125/75 in those with significant proteinuria per KDIGO guidelines)
3.3 High-Risk Patients
Profile: Proteinuria > 1 g/day, OR hypertension, OR rising creatinine / declining GFR.
As above, titrated to maximum tolerated dose.
Renal biopsy: only in selected patients who have proteinuria [2] — at this stage, biopsy is indicated to:
- Confirm TBMD (EM: thin GBM) and exclude alternative/superimposed diagnoses
- Look for superimposed FSGS, IgAN, or other pathology that would change management
- It is unclear whether TBMD contributed to FSGS in these patients or just an incidental finding [2] — but if FSGS is found, immunosuppressive therapy may be warranted
If progressive CKD develops, management follows standard CKD guidelines:
| CKD Complication | Management | Why |
|---|---|---|
| Hypertension | ACEI/ARB first-line; add CCB or diuretic if needed; target < 130/80 | HTN accelerates glomerulosclerosis |
| Proteinuria | ACEI/ARB; dietary sodium restriction (< 2g/day); moderate protein restriction (0.8 g/kg/day) | Reduces intraglomerular pressure and proteinuria; high sodium blunts ACEI/ARB effect |
| Metabolic acidosis | Sodium bicarbonate supplementation | Acidosis accelerates muscle wasting and bone disease |
| Anaemia | EPO (erythropoietin-stimulating agents), iron supplementation | CKD → ↓ EPO production by peritubular fibroblasts |
| Mineral bone disease | Phosphate binders, vitamin D analogues, manage PTH | CKD → phosphate retention → secondary hyperparathyroidism → renal osteodystrophy |
| Hyperkalaemia | Dietary restriction, loop diuretics, potassium binders (patiromer, SZC) | CKD → ↓ K+ excretion; ACEI/ARB further reduce K+ excretion |
| Cardiovascular risk | Statin, BP control, smoking cessation, diabetes control | CKD is a major CV risk factor |
3.4 End-Stage Kidney Disease (ESKD) — Rare but Possible
In the very rare TBMD patient who progresses to ESKD:
Renal transplant: preferred option over dialysis [2]
Why transplant is preferred:
- Better long-term survival and quality of life vs dialysis
- No recurrence of TBMD in the graft — the donor kidney has normal COL4A3/4 genes → normal GBM
- Unlike IgAN or FSGS, TBMD does not "recur" in the transplanted kidney
Should evaluate carefully for any co-existent Alport syndrome before living-related donor transplantation [2]
Why this matters enormously:
- If the patient actually has Alport syndrome rather than TBMD, a living-related donor (family member) may carry the same COL4A mutation → donating a kidney with the same structural defect → suboptimal graft
- Worse still, a related donor may be a carrier (heterozygous) and donating would leave them with a solitary kidney AND a subtle GBM defect
- Always perform genetic testing on both recipient and potential related donor before living-related donation
May develop de novo anti-GBM disease (3%) as some may express anti-α5 or anti-α3 Ab → attack graft kidney GBM → crescentic GN → plasmapheresis and cyclophosphamide [2]
Why does this happen? This is a fascinating immunological phenomenon:
- Patients with Alport syndrome (and some with TBMD who are homozygous for certain deletions) have never been exposed to the normal α3/α4/α5 collagen IV epitopes — their immune system does not recognise these as "self"
- When they receive a transplant with a normal GBM containing α3/α4/α5 chains, the immune system may mount an alloimmune response against these "foreign" collagen epitopes
- This produces anti-GBM antibodies (anti-α3 or anti-α5) → linear IgG deposition on graft GBM → crescentic GN → rapid graft loss if not treated
- Treatment: Plasmapheresis (to remove circulating antibodies) + cyclophosphamide (to suppress antibody production)
Exam Alert — De Novo Anti-GBM Disease Post-Transplant
This is a favourite exam question. Remember: it occurs in ~3% of Alport syndrome patients post-transplant, and can also (very rarely) occur in TBMD patients with large COL4A deletions. The mechanism is alloimmunity against the normal α3/α4/α5 collagen IV in the donor kidney. Treatment is plasmapheresis + cyclophosphamide. This is distinct from Goodpasture disease (which is autoimmune, not alloimmune).
4. Special Situations
- TBMD itself does not pose a significant risk in pregnancy
- Haematuria may fluctuate but does not predict pre-eclampsia
- ACEI/ARB must be stopped if the patient conceives (teratogenic — see above)
- Alternative antihypertensives if BP control needed: labetalol, nifedipine, methyldopa
- Monitor for proteinuria (which may increase physiologically in pregnancy) — distinguish from pre-eclampsia
- TBMD carriers can donate a kidney, but require:
- Thorough genetic counselling
- Confirmation that they do NOT have early Alport syndrome
- Understanding that donating a kidney with a thin GBM + becoming a single-kidney patient carries some theoretical risk
- Long-term follow-up post-donation
| Scenario | Counselling Points |
|---|---|
| One parent with TBMD (het COL4A3 or COL4A4) | 50% chance each child inherits the mutation → TBMD. If the other parent also carries a mutation in the same gene → 25% chance of homozygous child → AR Alport syndrome |
| Both parents with TBMD (both het COL4A3 or COL4A4) | 25% chance of AR Alport syndrome (homozygous); 50% TBMD; 25% unaffected |
| Consanguineous marriage | Higher risk of homozygosity → AR Alport syndrome |
| Risk Category | Clinical Profile | Management | Follow-up |
|---|---|---|---|
| Low risk | Isolated haematuria, no proteinuria, normal BP/GFR | Reassurance; education; lifestyle advice; no medication | Annual: urinalysis, uPCR/UACR, RFT, BP |
| Moderate risk | Proteinuria 0.5–1 g/d OR FHx of CKD | ACEI/ARB if proteinuria > 0.5–1 g/d; genetic testing | 6-monthly: urinalysis, uPCR, RFT, BP |
| High risk | Proteinuria > 1 g/d OR HTN OR rising Cr | ACEI/ARB max dose; renal biopsy; manage as CKD | 3–6 monthly; consider nephrology referral |
| ESKD | GFR < 15 mL/min | Renal transplant preferred over dialysis [2]; screen related donors for COL4A mutation | Post-transplant: monitor for de novo anti-GBM disease |
Common Management Errors
-
Do NOT start immunosuppression — TBMD is not an immune-mediated disease. Steroids, cyclophosphamide, mycophenolate have NO role (unless superimposed pathology like FSGS or IgAN is found on biopsy)
-
Do NOT biopsy every patient — biopsy is invasive and adds little in a patient with classic low-risk TBMD. Reserve it for proteinuria > 1 g/d, declining GFR, or diagnostic uncertainty
-
Do NOT discharge without follow-up — even though most patients do well, the ~5% who progress need to be caught early. Annual monitoring is the minimum
-
Do NOT use a related kidney donor without genetic screening — you may be transplanting a defective kidney and harming the donor
-
Do NOT combine ACEI + ARB ("dual RAAS blockade") — trials (ONTARGET, VA NEPHRON-D) showed increased hyperkalaemia, AKI, and no benefit in CKD outcomes
High Yield Summary
Core principle: TBMD has no specific treatment — management is risk-stratified monitoring and targeted ACEI/ARB therapy
Low risk (majority): Reassurance + annual monitoring (urinalysis, uPCR/UACR, RFT, BP)
When to treat with ACEI/ARB: Proteinuria > 0.5–1 g/day, OR hypertension, OR rising creatinine/declining GFR [2]
ACEI/ARB mechanism: Block angiotensin II → relax efferent arteriole → reduce intraglomerular pressure → reduce proteinuria and slow CKD progression
Transplant considerations:
- Renal transplant preferred over dialysis [2]
- Evaluate for co-existent Alport syndrome before living-related donor transplantation [2]
- De novo anti-GBM disease in ~3% post-transplant [2] → treat with plasmapheresis + cyclophosphamide
Never: Immunosuppression (unless superimposed pathology), dual RAAS blockade, biopsy everyone, use related donors without genetic screening
Active Recall - Management of TBMD
References
[1] Senior notes: Block A - Glomerular and Tubulo-interstitial Diseases and Acute Kidney Injury.pdf (Alport syndrome and TBMD section) [2] Senior notes: Ryan Ho Urogenital.pdf (Section 3.2.4 Thin Basement Membrane Disease)
Complications of Thin Basement Membrane Disease
TBMD is, by definition, one of the most benign glomerular conditions in nephrology. The fact that it was historically called "benign familial haematuria" tells you that most patients live entirely normal lives with nothing more than microscopic haematuria on a urine dipstick. However, calling it entirely complication-free would be inaccurate and dangerous for exams. There are complications — they are just uncommon, nuanced, and disproportionately important to understand.
The complications can be conceptually divided into:
- Direct complications of TBMD itself (disease-related)
- Complications of the underlying genetic defect (when the diagnosis is actually more severe than initially thought)
- Complications related to management (iatrogenic/treatment-related)
- Psychosocial complications (often overlooked)
2. Disease-Related Complications
This is the most clinically significant complication of TBMD, although it affects only a minority.
Prognosis is usually benign but a minority (5%) develop progressive CKD, especially those who have proteinuria or positive family history of CKD [2]
Why does a subset progress?
The mechanism is not completely understood, but the leading hypotheses are:
-
"Second hit" theory: The thin, fragile GBM is more susceptible to additional insults. Superimposed haemodynamic stress (hypertension), metabolic injury (diabetes, obesity), or a second glomerular disease (IgAN, FSGS) acts as a "second hit" on an already vulnerable GBM → accelerates glomerulosclerosis beyond what the second hit alone would cause.
-
Hyperfiltration injury: When some nephrons are damaged (by any cause), the remaining nephrons compensate by increasing single-nephron GFR (Brenner's hyperfiltration hypothesis). In a patient with an inherently thin GBM, this increased hydrostatic pressure across a fragile membrane may be particularly damaging, creating a positive feedback loop:
Thin GBM → some nephron loss → compensatory hyperfiltration → more GBM stress → more nephron loss → progressive CKD
-
Genetic modifier effects: Some heterozygous COL4A3/4 mutations may be more pathogenic than others (e.g., truncating mutations vs missense). Additional polymorphisms in podocyte or GBM-related genes may modify the phenotype.
Risk factors for progression [2]:
- Proteinuria (the single most important predictor)
- Positive family history of CKD
- Hypertension
- Male sex (less certain, but mirrors Alport data)
- Specific mutation type (truncating > missense, though data are limited)
Proteinuria is both a complication and a prognostic marker in TBMD. When it develops, it signals that the GBM defect is now significant enough to disrupt not just the size barrier (allowing RBCs through) but also the functional permselectivity of the filtration barrier.
Pathophysiology of proteinuria in TBMD:
- The thin GBM may undergo focal areas of more severe structural disruption over decades
- Podocyte injury follows — as podocytes attempt to cover a structurally compromised GBM, they may undergo foot process effacement and eventually detach (podocytopenia)
- Loss of podocytes exposes the GBM → further protein leak → tubulointerstitial injury from protein overload in tubular fluid → fibrosis
Heterozygous defect is sufficient to disrupt GBM architecture to result in haematuria, but not sufficient to provoke secondary processes that result in proteinuria and progressive CKD as in Alport syndrome [2] — this holds true for the majority, but the minority who develop proteinuria are demonstrating that their particular mutation/context DOES provoke these secondary processes.
It is unclear whether TBMD contributed to FSGS in these patients or just an incidental finding [2]
This is a genuinely unresolved question in nephrology. Some TBMD patients who undergo biopsy for progressive proteinuria are found to have FSGS. Two interpretations exist:
| Interpretation | Explanation |
|---|---|
| Causal | The thin GBM leads to chronic podocyte stress → podocyte loss → areas of bare GBM → segmental sclerosis (this is essentially the mechanism of all secondary FSGS) |
| Coincidental | TBMD is present in 5–9% of the population; FSGS is also common; some overlap is statistically inevitable |
The truth likely lies in between — TBMD may lower the threshold for developing FSGS in the presence of other risk factors (obesity, hypertension, hyperfiltration from reduced nephron mass).
Clinical significance: When FSGS is found on biopsy in a TBMD patient, management changes — immunosuppression (e.g., steroids ± calcineurin inhibitors) may be considered if the FSGS is thought to be primary, or ACEI/ARB + lifestyle modification if secondary.
Given that both TBMD (5–9% prevalence) and IgA nephropathy (the most common glomerulonephritis worldwide) are common, they can coexist in the same patient. When they do:
- The patient may present with features atypical for "pure" TBMD: synpharyngitic gross haematuria, heavier proteinuria, declining GFR
- Renal biopsy shows thin GBM on EM AND mesangial IgA deposits on IF
- Management must address the IgAN component (ACEI/ARB, possibly immunosuppression if MEST-C score warrants it)
Although gross haematuria is unusual ( < 10%) in TBMD [1], when it occurs it can cause:
| Complication of Gross Haematuria | Mechanism |
|---|---|
| Acute kidney injury (AKI) | RBC casts and debris can obstruct renal tubules → acute tubular obstruction → transient AKI. This is similar to what happens in severe IgAN flares |
| Flank pain | Renal capsule distension from parenchymal congestion; passage of clots through the collecting system |
| Anaemia | Rarely, recurrent gross haematuria can contribute to iron-deficiency anaemia (urinary iron loss), though this is more of a concern in Alport syndrome or IgAN |
| Patient anxiety | Visible blood in the urine is alarming — may prompt unnecessary investigations if the diagnosis is not established |
ESKD is an extremely rare complication of "pure" TBMD. When it occurs, consider:
- Was the original diagnosis correct? Could this be Alport syndrome (autosomal dominant variant)?
- Is there a superimposed second glomerular disease?
- Are there non-renal accelerating factors (uncontrolled hypertension, diabetes)?
If ESKD does develop:
- Renal transplant: preferred option over dialysis [2]
- Should evaluate carefully for any co-existent Alport syndrome before living-related donor transplantation [2]
3. Complications Related to Genetic/Diagnostic Overlap with Alport Syndrome
This is arguably the most important "complication" — not of the disease itself, but of diagnostic error. Because TBMD and Alport syndrome sit on a genetic continuum, there are scenarios where the initial diagnosis of TBMD is revised:
| Scenario | Consequence |
|---|---|
| Heterozygous COL4A3/4 with dominant-negative effect | Some mutations produce a dominant-negative protein that disrupts the entire α3α4α5 network (not just haploinsufficiency). These patients progress like autosomal dominant Alport syndrome despite being heterozygous |
| Female X-linked Alport carrier misdiagnosed as TBMD | Women with X-linked Alport syndrome are heterozygous carriers of the disease mutation. Almost all have some degree of haematuria, and some develop renal failure [lyonization] [1]. Random X-inactivation means some glomeruli express the mutant allele exclusively → progressive damage |
| Digenic inheritance | Patient heterozygous for COL4A3 AND COL4A4 (or COL4A3 AND COL4A5) — compound effect worse than single heterozygosity |
Why this matters clinically:
- A patient labelled "TBMD" who actually has mild Alport syndrome will not receive appropriate genetic counselling about offspring risk
- Related family members may not be screened for SNHL or ocular disease
- Living-related donor transplantation planning may be compromised
Clinical Pearl — Always Reassess
If a patient with a diagnosis of TBMD develops unexplained progressive proteinuria, declining GFR, or new sensorineural hearing loss, you must reconsider the diagnosis. Perform formal pure-tone audiometry, ophthalmological assessment, and COL4A3-5 genetic testing if not already done.
May develop de novo anti-GBM disease (3%) as some may express anti-α5 or anti-α3 Ab → attack graft kidney GBM → crescentic GN → plasmapheresis and cyclophosphamide [2]
Although this is primarily a complication of Alport syndrome patients post-transplant, it is discussed here because:
- Some TBMD patients who reach ESKD (especially those with large deletions encompassing the α3 or α4 encoding region) may never have expressed the normal α3α4α5 epitopes
- Upon receiving a normal donor kidney, their immune system encounters these "foreign" collagen epitopes for the first time → alloimmune anti-GBM antibody production
Pathophysiology from first principles:
Recipient has never produced normal α3/α4 collagen → immune system never developed tolerance
↓
Transplant introduces kidney with normal α3α4α5 GBM
↓
Recipient T cells recognise α3/α5 epitopes as foreign → help B cells
↓
B cells produce anti-α3 or anti-α5 IgG antibodies
↓
Antibodies bind linearly to graft GBM → complement activation → crescentic GN
↓
Rapid graft loss if untreatedManagement: Plasmapheresis (remove circulating antibodies) + cyclophosphamide (suppress antibody production) + high-dose corticosteroids
4. Treatment-Related Complications
Since ACEI/ARB is given for proteinuria > 0.5–1 g/day or hypertension or rising creatinine/declining GFR [2], the complications of these drugs are relevant:
| Complication | Mechanism | Monitoring / Management |
|---|---|---|
| Hyperkalaemia | ACEI/ARB → ↓ aldosterone → ↓ K+ excretion in distal tubule → K+ accumulates | Check K+ at 1–2 weeks post-initiation; if K+ > 5.5, reduce dose or stop; dietary potassium restriction; potassium binders (SZC, patiromer) |
| AKI from excessive GFR drop | ACEI/ARB → efferent arteriolar dilation → ↓ intraglomerular pressure → ↓ GFR. Up to 30% creatinine rise is acceptable; > 30% suggests renal artery stenosis | Check creatinine 1–2 weeks post-initiation; if > 30% rise, investigate renal artery stenosis and withhold ACEI/ARB |
| Chronic cough (ACEI only) | ACEI blocks degradation of bradykinin → bradykinin accumulates in lung tissue → stimulates C-fibres → cough reflex | Switch to ARB (which does not affect bradykinin metabolism) |
| Angioedema (ACEI only) | Bradykinin-mediated vasodilation and increased vascular permeability → swelling of lips, tongue, airways | Stop ACEI immediately; do NOT switch to ARB if severe angioedema (small cross-reactivity risk); manage airway |
| Teratogenicity | ACEI/ARB disrupt foetal kidney development → renal agenesis, oligohydramnios, Potter sequence | Absolutely contraindicated in pregnancy; counsel all women of childbearing age; stop immediately if pregnancy confirmed |
Renal biopsy: only in selected patients who have proteinuria [2]. When performed, potential complications include:
| Complication | Frequency | Mechanism |
|---|---|---|
| Perirenal haematoma | ~10–15% (usually small, self-limiting) | Puncture of renal parenchymal vessels; usually contained by renal capsule |
| Macroscopic haematuria | ~3–5% | Puncture communicates with collecting system → blood in urine; usually self-limiting |
| AV fistula | ~1% | Needle traverses adjacent artery and vein creating a fistulous connection; usually closes spontaneously |
| Severe haemorrhage requiring transfusion/intervention | < 1% | Large vessel injury; risk increased with bleeding diathesis, severe hypertension |
| Loss of kidney (nephrectomy) | Extremely rare | Catastrophic bleeding unresponsive to conservative measures |
These are often overlooked in medical notes but are real and significant, especially since TBMD is frequently diagnosed in children and young adults:
| Complication | Explanation |
|---|---|
| Anxiety and "disease label" burden | Being told you have a "kidney disease" can cause significant anxiety, even when the prognosis is excellent. Parents of affected children may be particularly anxious |
| Over-investigation | Without a clear diagnosis, patients may undergo repeated blood tests, imaging, and even unnecessary biopsies. Each investigation adds stress and cost |
| Insurance and employment implications | In Hong Kong, a diagnosis of "kidney disease" may affect health or life insurance premiums. Patients should be counselled that TBMD carries an excellent prognosis |
| Reproductive counselling anxiety | Heterozygous carriers must understand the risk of homozygous (AR Alport) offspring if their partner is also a carrier — this can cause significant anxiety around family planning |
| Complication | Frequency | Mechanism | Detection / Monitoring |
|---|---|---|---|
| Progressive CKD | ~5% [2] | Second hits on vulnerable thin GBM; hyperfiltration injury; genetic modifiers | Annual uPCR, RFT, BP |
| Proteinuria development | Minority | Progressive podocyte stress over thin GBM → barrier dysfunction | Annual uPCR/UACR |
| Superimposed FSGS | Rare, unclear if causal or coincidental [2] | Podocyte loss → segmental sclerosis ± hyperfiltration | Renal biopsy when indicated |
| Superimposed IgAN | Uncommon but possible | Coincidence of two common conditions | Renal biopsy (mesangial IgA on IF) |
| Gross haematuria episodes | < 10% [1] | More extensive GBM ruptures, often triggered by URTI | Clinical observation; reassurance |
| AKI from gross haematuria | Very rare | Tubular obstruction by RBC casts | Monitor RFT during episodes |
| ESKD | Extremely rare | Progressive CKD reaching GFR < 15 mL/min | RFT trend over years |
| De novo anti-GBM disease post-transplant | ~3% [2] | Alloimmunity against normal α3/α5 collagen IV in graft | Post-transplant biopsy if graft dysfunction |
| Misdiagnosis (actually Alport) | Variable | Heterozygous dominant-negative mutations; female X-linked carriers | PTA, ophthalmology, genetic testing |
| ACEI/ARB side effects | Dose-dependent | Hyperkalaemia, AKI, cough, angioedema, teratogenicity | K+, creatinine at 1–2 weeks; pregnancy counselling |
| Biopsy complications | ~10–15% minor | Perirenal haematoma, macroscopic haematuria, AV fistula | Post-biopsy monitoring (vitals, urine, USS) |
High Yield Summary
Most patients with TBMD have NO complications — the prognosis is benign for the vast majority.
Key complications to know:
- Progressive CKD (~5%) — most important; risk factors include proteinuria, FHx of CKD, hypertension
- Superimposed FSGS — unclear if TBMD is causal or coincidental; biopsy needed to diagnose
- De novo anti-GBM disease (~3%) post-transplant — alloimmunity against normal α3/α5 collagen IV in graft; treated with plasmapheresis + cyclophosphamide
- Misdiagnosis as TBMD when actually Alport syndrome — always reassess if features of progression, SNHL, or ocular disease emerge
- ACEI/ARB side effects — hyperkalaemia, AKI, cough, teratogenicity
The most important complication is the one you miss: Alport syndrome masquerading as TBMD.
Active Recall - Complications of TBMD
References
[1] Senior notes: Block A - Glomerular and Tubulo-interstitial Diseases and Acute Kidney Injury.pdf (Alport syndrome and TBMD section) [2] Senior notes: Ryan Ho Urogenital.pdf (Section 3.2.4 Thin Basement Membrane Disease)
High Yield Summary
Definition: TBMD = hereditary disorder with diffuse GBM thinning (150–225 nm vs normal 300–400 nm) on EM, presenting as isolated glomerular haematuria
Genetics: Heterozygous COL4A3/COL4A4 mutations (AD inheritance) = "carrier state" of AR Alport syndrome
Epidemiology: 5–9% prevalence but < 1% clinically diagnosed
Key Clinical Features:
- Persistent/intermittent microscopic haematuria (gross haematuria unusual, < 10%)
- Normal BP, normal GFR, minimal/no proteinuria
- No extrarenal manifestations (no SNHL, no ocular disease — unlike Alport)
- FHx of haematuria in 30–50%
Pathology: Normal LM, negative IF, thin GBM on EM
Prognosis: Generally benign, but ~5% may progress (especially with proteinuria or FHx of CKD)
Key Distinctions from Alport Syndrome:
- Alport = X-linked (80%), progressive CKD, SNHL, ocular disease, basket-weave GBM on EM
- TBMD = AD, benign course, no extrarenal features, uniformly thin GBM on EM
Diagnosis: EM (gold standard for morphology), genetic testing (COL4A3/4 mutations), clinical context
High Yield Summary
Two-level differential approach:
- Level 1: Glomerular (dysmorphic RBCs, casts) vs. non-glomerular (urological workup mandatory)
- Level 2: Among the "Big Three" of isolated glomerular haematuria — IgAN, Alport syndrome, TBMD
Key differentiators for TBMD:
- Gross haematuria unusual (< 10%) — cf. common in IgAN and Alport
- AD inheritance, FHx of haematuria (not CKD)
- No extrarenal features (no SNHL, no ocular disease)
- Normal GFR, minimal proteinuria
Most important tool: History + urinalysis of family members
Must exclude: Non-glomerular causes (especially urological malignancy in > 40 y/o); other glomerulopathies with serologies (C3/C4, ANA, ANCA, anti-GBM)
Beware: Female X-linked Alport carriers can mimic TBMD; resolve with genetic testing
High Yield Summary
Diagnosis of TBMD is usually clinical — based on isolated glomerular haematuria + normal RFT/BP + AD FHx of benign haematuria + absence of extrarenal features + negative serologies.
Key investigations:
- Urinalysis: Dysmorphic RBCs ± RBC casts confirm glomerular origin
- Urine protein quantification: < 1 g/day (uPCR or UACR preferred over 24h collection)
- RFT: Normal creatinine and eGFR
- Serologies: C3/C4, ANA, ANCA, anti-GBM — all normal; purpose is to exclude immune-mediated GN
- PTA: Normal (excludes Alport syndrome SNHL)
- Imaging: USG kidneys normal; cystoscopy/CTU for patients > 40 years to exclude urological malignancy
- Renal biopsy: Reserved for proteinuria > 1 g/day, declining GFR, diagnostic uncertainty, or donor evaluation → EM shows GBM 150–225 nm, LM normal, IF negative
- Genetic testing: Heterozygous COL4A3/4 mutation — increasingly first-line; definitive
- Family screening: Urinalysis + RFT + PTA of relatives
Biopsy indications: Proteinuria > 1 g/day, rising Cr, potential kidney donors, genetic counselling
High Yield Summary
Core principle: TBMD has no specific treatment — management is risk-stratified monitoring and targeted ACEI/ARB therapy
Low risk (majority): Reassurance + annual monitoring (urinalysis, uPCR/UACR, RFT, BP)
When to treat with ACEI/ARB: Proteinuria > 0.5–1 g/day, OR hypertension, OR rising creatinine/declining GFR [2]
ACEI/ARB mechanism: Block angiotensin II → relax efferent arteriole → reduce intraglomerular pressure → reduce proteinuria and slow CKD progression
Transplant considerations:
- Renal transplant preferred over dialysis [2]
- Evaluate for co-existent Alport syndrome before living-related donor transplantation [2]
- De novo anti-GBM disease in ~3% post-transplant [2] → treat with plasmapheresis + cyclophosphamide
Never: Immunosuppression (unless superimposed pathology), dual RAAS blockade, biopsy everyone, use related donors without genetic screening
High Yield Summary
Most patients with TBMD have NO complications — the prognosis is benign for the vast majority.
Key complications to know:
- Progressive CKD (~5%) — most important; risk factors include proteinuria, FHx of CKD, hypertension
- Superimposed FSGS — unclear if TBMD is causal or coincidental; biopsy needed to diagnose
- De novo anti-GBM disease (~3%) post-transplant — alloimmunity against normal α3/α5 collagen IV in graft; treated with plasmapheresis + cyclophosphamide
- Misdiagnosis as TBMD when actually Alport syndrome — always reassess if features of progression, SNHL, or ocular disease emerge
- ACEI/ARB side effects — hyperkalaemia, AKI, cough, teratogenicity
The most important complication is the one you miss: Alport syndrome masquerading as TBMD.
Alport Syndrome
Alport syndrome is a hereditary nephropathy caused by mutations in type IV collagen genes, characterized by progressive glomerulonephritis, sensorineural hearing loss, and ocular abnormalities.
Post-Streptococcal Glomerulonephritis
Post-streptococcal glomerulonephritis is an immune complex-mediated glomerulonephritis occurring 1–3 weeks after group A β-hemolytic streptococcal infection, characterized by hematuria, proteinuria, edema, and hypertension.